[Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers].
G E N, 1977/1-1977/3;31(3):149-55.
Vilela MD, Siqueira WA, Rodriguez LD, Domingues SH, Rodrigues FD
PMID: 97122
Abstract
Patients with positive serum HBAg reactions were treated with Viramid (1-beta-D-ribofuranozyl-1, 2, 4-triazol-3-carboxamide) a new anti-viral drug. Of the patients involved in this study, 5 had chronic hepatitis or prolonged hepatitis and 12 were healthy HBAg carriers. Results obtained suggest that the drug had some action on serum HBAg titres with a decrease or negativation of HBAg serum titres in peripheric blood, the evaluation of which was immediately seen by employing the counterimmune electrophoresis technique.
MeSH terms
Adolescent; Adult; Antiviral Agents; Capsules; Carrier State; Child; Drug Evaluation; Female; Hepatitis A; Hepatitis B Surface Antigens; Humans; Male; Middle Aged; Ribavirin; Ribonucleosides
More resources
EndNote: Download